Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population

Summary

Hepatic veno-occlusive disease (VOD) is a severe complication after hematopoietic stem cell transplantation (HSCT). Recent studies, mainly in adults receiving HSCT, have identified an increase in the plasminogen activator inhibitor-1 (PAI-1) as a possible marker of VOD. To confirm this finding, the fibrinolytic, coagulation and liver function parameters were assayed before and weekly for 1 month after 61 HSCT performed in 53 consecutive children. Non-VOD patients had a slight increase in t-PA antigen, fibrinogen and P-selectin levels, as well as a mildly longer aPTT and a drop in antithrombin after HSCT. The 6 children with VOD (9.84%) had an early and significant increase in PAI-1 antigen and activity (p< 0.0001), t-PA antigen (p< 0.0001) and D-dimer (p< 0.01) levels, and a decrease in plasminogen, α2-antiplasmin and PT emerged 2(±1) days before the clinical diagnosis of VOD by comparison with mean post-HSCT values in the non-VOD patients. Significant differences were also detected for these parameters and antithrombin levels between non-VOD and VOD patients soon after the clinical onset of VOD, whereas the rise in bilirubin levels became significant only later on. In conclusion, variations in fibrinolytic test findings after HSCT, and PAI-1 in particular, may facilitate the early diagnosis of VOD in pediatric patients after HSCT.

Keywords

Hematopoietic stem cell transplantation - paediatric - veno-occlusive disease - plasminogen activator inhibitor - busulphan

• References

• 1 Carreras E, Granena A, Rozman C. Hepatic venoocclusive disease after bone marrow transplant. Blood Rev 1993; 7: 43-51.
• 2 Bearman SJ. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-20.
• 3 McDonald GB, Hinds MS, Fisher LD. et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-67.
• 4 Carreras E, Bertz H, Arcese W. et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. Blood 1998; 92: 3599-604.
• 5 Jones RJ, Lee KSK, Beschorner WE. et al. Venocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-83.
• 6 Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplantation. Eur J Haematol 2000; 64: 281-91.
• 7 Shulman HM, Hinterberger W. Hepatic veno-occlusive disease – liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
• 8 Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-58.
• 9 McDonald GB, Sharma P, Matthews DE. et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-22.
• 10 Heikinheimo H, Halila R, Fasth A. Serum procollagen type III is an early and sensitive marker for venoocclusive disease of the liver in children undergoing bone marrow transplantation. Blood 1994; 83: 3036-40.
• 11 Rio B, Bauduer F, Arrago JP. et al. N-terminal peptide of type III procollagen: a marker for the development of hepatic veno-occlusive disease after BMT and a basis for determining the timing of prophylactic heparin. Bone Marrow Transplant 1993; 11: 471-2.
• 12 Faioni EM, Mannucci PM. Venocclusive disease of the liver after bone marrow transplantation: The role of hemostasis. Leuk Lymphoma 1997; 25: 233-45.
• 13 Barzabacchi A, Scrobohaci ML, Gisselbrecht C. et al. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease. Nouv Rev Fr Hematol 1993; 35: 135-40.
• 14 Vannucchi AM, Ravanelli D, Longo G. et al. Early hemostatic alterations following bone marrow transplantation: a prospective study. Haematologica 1994; 79: 519-25.
• 15 Collins P, Roderck A, O’Brein D. et al. Factor VIIa and other haemostatic variables following bone marrow transplantation. Thromb Haemost 1994; 72: 28-32.
• 16 Faioni EM, Krachmalnicoff A, Bearman I S. et al. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood 1993; 81: 3458-62.
• 17 Holler E, Kolb HJ, Moller A. et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-6.
• 18 Wiman B, Chmielwska J, Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644-7.
• 19 Sprengers ED, Akkerman JWN, Jansen BJ. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thromb Haemost 1986; 55: 325-9.
• 20 Alessi MC, Juan-Vague I, Kooistra T. et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line HepG2. Thromb Haemost 1988; 60: 491-4.
• 21 van Hinsbergh VW, Kooistra T, van den Berg EA. et al. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-73.
• 22 Eren M, Painter CA, Gleaves LA. et al. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. J Thromb Haemost 2003; 1: 2389-96.
• 23 Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic diseases. Thromb Haemost 1995; 74: 71-6.
• 24 Salat C, Holler E, Reinhardt B. et al. Parameters of the fibrinolytic system in patients undergoing BMT: Elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747-50.
• 25 Salat C, Holler E, Hans-Jochem K. et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997; 89: 2184-8.
• 26 Kaleelrahman M, Eaton JD, Leeming D. et al. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide. Hematology 2003; 8: 91-5.
• 27 Lee JH, Lee KH, Lee JH. et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087-94.
• 28 Richardson PG, Murakami C, Jin Z. et al. Multiinstitutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-43.
• 29 Park Y-D, Yasui M, Yoshimoto T. et al. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation. Bone Marrow Transplant 1997; 19: 915-20.
• 30 Goodman JL, Winston DJ, Greenfield RA. et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-51.
• 31 Chopra R, Eaton JD, Grassi A. et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-9.
• 32 Bearman I S, Appelbaum FR, Buckner CD. et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-8.
• 33 Clauss A. Gerinnungsphysiologishe schnellmethode zur bestimmung des fibrinogens. Acta Haematol 1957; 17: 237-42.
• 34 De Clerck PJ, Alessi MC, Verstreken M. et al. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibodybased enzyme-linked immunoassay. Blood 1988; 71: 220-5.
• 35 Holvoet P, Cleemput H, Collen D. Assay of tissue plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemost 1985; 54: 684-7.
• 36 Eriksson E, Rånby M, Gyrender E. et al. Determination of the plasminogen activator inhibitor in plasma using t-PA and chromogenic single-point poly- D-Lysine stimulated assay. Thromb Res 1988; 50: 91-101.
• 37 Soria C, Soria J, Samama MM. Dosage du plasminogène à l’aide d’un substrate chromogène tripeptidique. Pathol Biol 1976; 24: 725-9.
• 38 Fijnheer R, Frijns CJM, Korteweg J. et al. The origin of P-selectin as a circulating plasma protein. Thromb Haemost 1997; 77: 1081-5.
• 39 Grochow LB, Jones RJ, Brundrett RB. et al. Pharmacokinetics of busulphan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
• 40 Hassan M, Oberg G, Bekassy AN. et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-4.
• 41 Barker CC, Butzner JD, Anderson RA. et al. Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2003; 32: 79-87.
• 42 Horn B, Reiss U, Matthay K. et al. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002; 29: 409-15.
• 43 Notoya A, Sawada K, Ieko M. et al. Subclinical alterations in coagulation and fibrinolysis in patients undergoing autologous peripheral blood stem cell transplantation. Leuk Lymphoma 1998; 28: 405-13.
• 44 Luzzatto G, Cella G, Messina C. et al. Markers of endothelial function in pediatric stem cell transplantation for acute leukemia. Med Pediatr Oncol 2003; 40: 9-12.
• 45 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
• 46 Sartori MT, Patrassi GM, Rigotti P. et al. Improved fibrinolytic capacity after withdrawal of steroid immunosuppression in renal transplant recipients. Transplantation 2000; 69: 2116-21.
• 47 Juhan-Vague I, Alessi MC, Mavri A. et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-9.
• 48 Korte W. Veno-occlusive disease of the liver after bone marrow transplantation: is hypercoagulability really part of the problem?. Blood Coag Fibrinol 1997; 8: 367-81.